⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 1, 2025Open Access

Supplementary Figure S8 from Blocking NRF2 Translation by Inhibition of Cap-Dependent Initiation Sensitizes Lymphoma Cells to Ferroptosis and CAR T-cell Immunotherapy

Paola Manara Austin D. Newsam Venu Venkatarame Gowda Saralamma Tyler Andrew Cunningham Drew Lazenby J.J.David Ho Marco Vincenzo Russo Abdessamad Youssfi Alaoui Dhanvantri Chahar Alicia Bilbao Martinez Nikolai Fattakhov Alexandra Marie Carbone Olivia Barbara Farag Alexa Marie Barroso Kyle Hoffman Francesco Maura Daniel Bilbao Jonathan H. Schatz

View Full Paper

Ask AI

Bookmark

Share

Key Points

Blocking NRF2 translation increases lymphoma cell sensitivity to ferroptosis and improves CAR T-cell therapy outcomes.
In vivo tumor growth studies reveal that zotatifin enhances the efficacy of CAR T immunotherapy in lymphoma models.
CAR T cell co-culture assays confirm the synergistic effect of targeting NRF2 translation alongside CAR T-cell treatment.
These findings suggest a promising therapeutic strategy for lymphoma by combining zotatifin with immunotherapy.

Implication

Experimental analysis demonstrates tumor growth reduction using zotatifin with CAR T-cell therapy, indicating synergy in lymphoma treatment.

Abstract

CAR T cell co-culture assays and in vivo tumor growth studies assessing the synergy of zotatifin with CAR T immunotherapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Manara et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a21a4a https://doi.org/10.1158/0008-5472.30255173

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S2 from Blocking NRF2 Translation by Inhibition of Cap-Dependent Initiation Sensitizes Lymphoma Cells to Ferroptosis and CAR T-cell Immunotherapy2025
2Supplementary Figure S1 from Blocking NRF2 Translation by Inhibition of Cap-Dependent Initiation Sensitizes Lymphoma Cells to Ferroptosis and CAR T-cell Immunotherapy2025
3Supplementary Figure S7 from Blocking NRF2 Translation by Inhibition of Cap-Dependent Initiation Sensitizes Lymphoma Cells to Ferroptosis and CAR T-cell Immunotherapy2025
4Supplementary Figure S6 from Blocking NRF2 Translation by Inhibition of Cap-Dependent Initiation Sensitizes Lymphoma Cells to Ferroptosis and CAR T-cell Immunotherapy2025
5Supplementary Figure S4 from Blocking NRF2 Translation by Inhibition of Cap-Dependent Initiation Sensitizes Lymphoma Cells to Ferroptosis and CAR T-cell Immunotherapy2025

Supplementary Figure S5 from Blocking NRF2 Translation by Inhibition of Cap-Dependent Initiation Sensitizes Lymphoma Cells to Ferroptosis and CAR T-cell Immunotherapy2025
Supplementary Figure S3 from Blocking NRF2 Translation by Inhibition of Cap-Dependent Initiation Sensitizes Lymphoma Cells to Ferroptosis and CAR T-cell Immunotherapy2025
Data from Blocking NRF2 Translation by Inhibition of Cap-Dependent Initiation Sensitizes Lymphoma Cells to Ferroptosis and CAR T-cell Immunotherapy2025